TNFSF11 and rheumatoid arthritis: Two phase 2 studies using a RANKL-specific monoclonal blocking antibody (denosumab) have been conducted in patients with RA receiving methotrexate and both demonstrated significant inhibition of bone erosion progression compared to the placebo without the inhibition of inflammation itself [37,38].